FDA Inspection
Novartis Pharmaceuticals CorporationNovartis Pharmaceuticals Corporation – FDA Inspection, Feb 6, 2026
Record Details
This FDA Inspection record concerns Novartis Pharmaceuticals Corporation, with an inspection on February 6, 2026, issued by the New Jersey District Office, covering biologics.
View Company Profile
ID · dda9986d-7403-4915-9abe-66007c22736d
Inspection Facts
- Inspection number
- 1300144
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
FDA Citations
3- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Novartis Pharmaceuticals Corporation
4| Date | Classification | Office | Project area |
|---|---|---|---|
| August 8, 2024 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| December 9, 2022 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| August 21, 2019 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| April 7, 2017 | Not classified | New Jersey District Office |
Other documents for Novartis Pharmaceuticals Corporation
- FDA Inspection 1245942 - 2024-08-08
- FDA Inspection 1194474 - 2022-12-09
- FDA Inspection 1100101 - 2019-08-21
- FDA Inspection 1019194 - 2017-04-07
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.